phosphoglycerate kinase 1
Dernière mise à jour 18 Aug 2020
Respecte les directives éditoriales
- TéléchargerTélécharger
- Partager
- Language
- Discussion
- Ask Patient
- Version audio
- Ajouter aux sources préférées sur Google
La PGK1 gene provides instructions for making an enzyme called phosphoglycerate kinase. This enzyme is found in cells and tissues throughout the body, where it is involved in a critical energy-producing process known as glycolysis. During glycolysis, the simple sugar glucose is broken down to produce energy.
Sélections vidéo pour GènesBibliothèque vidéo
Normal function
La PGK1 gene provides instructions for making an enzyme called phosphoglycerate kinase. This enzyme is found in cells and tissues throughout the body, where it is involved in a critical energy-producing process known as glycolysis. During glycolysis, the simple sugar glucose is broken down to produce energy.
Phosphoglycerate kinase helps carry out a chemical reaction that converts a molecule called 1,3-diphosphoglycerate, which is produced during the breakdown of glucose, to another molecule called 3-phosphoglycerate. This reaction generates one molecule of adenosine triphosphate (ATP), which is the main energy source in cells.
Researchers suspect that phosphoglycerate kinase may have additional functions, although little is known about the other roles this enzyme may play in cells.
Conditions referring to this gene or chromosome
Other names
cell migration-inducing gene 10 protein
MGC117307
MGC142128
MGC8947
MIG10
PGK1_HUMAN
PGKA
primer recognition protein 2
PRP 2
Related patient information and medicines

Patient information leaflet
Maladies de stockage du glycogène
Maladies de stockage du glycogène are a group of inherited diseases. They result from a problem with one of the proteins (known as enzymes) involved in the conversion of glucose to glycogen, or the breakdown of glycogen back into glucose. They mostly tend to affect your liver and muscles. Most ar... Type II (Pompe's disease). Type VII (Tarui's disease)..

Patient information leaflet
Cancer primitif du foie
It is not likely to be curative for primary liver cancer but may shrink the tumour down to slow the progression of the disease. There are new medicines being developed for the treatment of liver cancer. For example, sorafenib is a type of medicine called a multi-targeted kinase inhibitor. National Institute for Health and Care Excellence (NICE).

Patient information leaflet
Tests de fonction hépatique
Tests de fonction hépatique are a set of blood tests commonly done to check on the health of your liver. Changes in liver function tests give a clue as to whether your liver is under strain, inflamed, infected or diseased, and how badly. The pattern of the liver functio... What does an abnormal ALT (SGPT), AST (SGOT) or creatine kinase level mean. AST.

Patient information leaflet
Dystrophie musculaire de Duchenne
The name Duchenne comes de the doctor who first studied this condition. How common est Dystrophie musculaire de Duchenne. About 1 in 3,500 boys in the UK are born with DMD. Gene la thérapie The National Institute for Health and Care Excellence (NICE) approved the use of ataluren in 2023. Although this has not been in use for long, it appears that this.

Patient information leaflet
dystrophie musculaire
dystrophie musculaire est un inherited (genetic) disorder causing muscle weakness. There are different types of muscular dystrophy, which vary as to how severe they are, ranging from very mild to severe. Also, if a child has delayed motor mil... MD may be diagnosed using one or more of the following tests: A blood test Blood tests for creatine kinase.

Patient information leaflet
Cancer de la bouche
Diagnosing mouth cancer Your healthcare professional may suspect mouth cancer if you have a lesion in your mouth (such as a sore, an ... Dr Krishna Vakharia , 16th October 2023 The National Institute for Health and Care Excellence (NICE) has recommended that a person should receive a diagnosis or ruling out of cancer within 28 days of being.
Lectures complémentaires et références
- phosphoglycerate kinase 1; MedlinePlus, National Library of Medicine.
- Beutler E. PGK deficiency. Br J Haematol. 2007 Jan;136(1):3-11. doi: 10.1111/j.1365-2141.2006.06351.x.
- Flanagan JM, Rhodes M, Wilson M, Beutler E. The identification of a recurrent phosphoglycerate kinase mutation associated with chronic haemolytic anaemia and neurological dysfunction in a family from USA. Br J Haematol. 2006 Jul;134(2):233-7. doi: 10.1111/j.1365-2141.2006.06143.x. Epub 2006 Jun 1.
- Noel N, Flanagan JM, Ramirez Bajo MJ, Kalko SG, Manu Mdel M, Garcia Fuster JL, Perez de la Ossa P, Carreras J, Beutler E, Vives Corrons JL. Two new phosphoglycerate kinase mutations associated with chronic haemolytic anaemia and neurological dysfunction in two patients from Spain. Br J Haematol. 2006 Feb;132(4):523-9. doi: 10.1111/j.1365-2141.2005.05882.x.
- Spiegel R, Gomez EA, Akman HO, Krishna S, Horovitz Y, DiMauro S. Myopathic form of phosphoglycerate kinase (PGK) deficiency: a new case and pathogenic considerations. Neuromuscul Disord. 2009 Mar;19(3):207-11. doi: 10.1016/j.nmd.2008.12.004. Epub 2009 Jan 20.
- Svaasand EK, Aasly J, Landsem VM, Klungland H. Altered expression of PGK1 in a family with phosphoglycerate kinase deficiency. Muscle Nerve. 2007 Nov;36(5):679-84. doi: 10.1002/mus.20859.
Partagez vos pensées ou expériences avec les autres dans notre communautés de patients.
Inscrivez-vous à la newsletter Patient
Votre dose hebdomadaire de conseils de santé clairs et fiables - rédigés pour vous aider à vous sentir informé, confiant et maître de la situation.
En vous abonnant, vous acceptez notre Politique de confidentialité. Vous pouvez vous désabonner à tout moment. Nous ne vendons jamais vos données.

